ALABAMA: New NIH-funded publication from UAB researchers using AI tool
Researchers from the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham used an AI tool known as mediKanren that flagged useful clinical evidence, helping them identify low-dose ketamine as a potential therapeutic target for activity-dependent neuroprotective protein (ADNP) syndrome. Findings from the NIH-funded trial were published in Human Genetics and Genomic Advances.
From the Summary:
Activity-dependent neuroprotective protein (ADNP) syndrome is a rare genetic condition associated with intellectual disability and autism spectrum disorder. Preclinical evidence suggests that low-dose ketamine may induce expression of ADNP and that neuroprotective effects of ketamine may be mediated by ADNP. The goal of the proposed research was to evaluate the safety, tolerability, and behavioral outcomes of low-dose ketamine in children with ADNP syndrome. We also sought to explore the feasibility of using electrophysiological markers of auditory steady-state response and computerized eye tracking to assess biomarker sensitivity to treatment.